Breast Cancer - Medical Oncology Clinical Trials Resources
Listed below are the Breast Cancer - Medical Oncology Clinical Trials offered at the Kaiser Permanente Santa Clara Medical Center.
| Title: |
EVALUATING THE ROLE OF OVARIAN FUNCTION SUPPRESSION AND THE ROLE OF EXEMESTANE AS ADJUVANT THERAPIES FOR PREMENOPAUSAL WOMEN WITH ENDOCRINE RESPONSIVE BREAST CANCER
SUPPRESSION OF OVARIAN FUNTION TRIAL |
| Phase: |
III |
| Modality: |
Ovarian Function Suppression and Hormonal Therapy |
| Sponsors and Collaborators: |
International Breast Cancer Study Group (IBCSG) and Clinical Trial Support Units (CTSU) |
| Protocol Number: |
IBCSG 24-02 |
| Weblink: |
LINK TO THE WEBSITE |
| Title: |
STUDY OF EPIRUBICIN + CYCLOPHOSPHAMIDE FOLLOWED BY DOCETAXEL PLUS TRASTUZUMAB AND BEVACIZUMAB GIVEN AS NEOADJUVANT THERAPY FOR HER-2 + LOCALLY ADVANCED BREAST CANCER OR GIVEN AS ADJUVANT THERAPY FOR HER-2 + PATHOLOGIC STAGE III BREAST CANCER |
| Phase: |
II |
| Modality: |
Chemotherapy |
| Sponsors and Collaborators: |
National Surgical Adjuvant Breast and Bowel Project (NSABP) |
| Protocol Number: |
FB-05 |
| Weblink: |
|
| Title: |
PROGRAM FOR THE ASSESSMENT OF CLINICAL CANCER TESTS (PACCT-1): TRIAL ASSIGNING INDIVIDUALIZED OPTIONS FOR TREATMENT: THE TAILORX TRIAL |
| Phase: |
III |
| Protocol Number: |
PACCT-1 |
| Sponsors and Collaborators: |
CTSU (Cancer Trial Support Unit) |
| Weblink: |
LINK TO THE WEB SITE |
| Title: |
A RANDOMIZED PHASE III TRIAL OF NEOADJUVANT THERAPY FOR PATIENTS WITH PALPABLE AND OPERABLE HER2-POSITIVE BREAST CANCER COMPARING THE COMBINATION OF TRASTUZUMAB PLUS LAPATINIB TO TRASTUZUMAB AND TO LAPATINIB ADMINISTERED WITH WEEKLY PACLITAXEL FOLLOWING AC ACCOMPANIED BY CORRELATIVE SCIENCE STUDIES TO IDENTIFY PREDICTORS OF PATHOLOGIC COMPLETE RESPONSE |
| Phase: |
III |
| Protocol Number: |
B41 |
| Sponsors and Collaborators: |
NSABP (National Surgical Adjuvant Breast and Bowel Project ) |
| Weblink: |
LINK TO THE WEB SITE |
| Title: |
A PHASE III CLINICAL TRIAL COMPARING TRASTUZUMAB GIVEN CONCURRENTLY WITH RADIATION THERAPY AND RADIATION THERAPY ALONE FOR WOMEN WITH HER2-POSITIVE DUCTAL CARCINOMA IN SITU RESECTED BY LUMPECTOMY |
| Phase: |
III |
| Protocol Number: |
B43 |
| Sponsors and Collaborators: |
NSABP (National Surgical Adjuvant Breast and Bowel Project ) |
| Weblink: |
LINK TO THE WEB SITE |
| Title: |
RANDOMIZED PLACEBO-CONTROLLED TRIAL OF ACETYL-L-CARNITINE (ALC) FOR THE PREVENTION OF TAXANE INDUCED NEUROPATHY PHASE III |
| Phase: |
III |
| Protocol Number: |
S0715 |
| Sponsors and Collaborators: |
SWOG (Southwest Oncology Group) |
| Weblink: |
LINK TO THE WEB SITE |
| Title: |
A RANDOMIZED, MULTICENTER, PHASE III OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF TRASTUZUMAB-MCC-DM1 VS.CAPECITABINE + LAPATINIB IN PATIENTS WITH HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO HAVE RECEIVED PRIOR TRASTUZUMAB-BASED THERAPY |
| Phase: |
III |
| Protocol Number: |
TDM4370g |
| Sponsors and Collaborators: |
Genentech |
| Weblink: |
LINK TO THE WEB SITE |
| Title: |
A PHASE III CLINICAL TRIAL COMPARING THE COMBINATION OF TC PLUS BEVACIZUMAB TO TC ALONE AND TO TAC FOR WOMEN WITH NODE-POSITIVE OR HIGH-RISK NODE-NEGATIVE, HER2-NEGATIVE BREAST CANCER |
| Phase: |
III |
| Protocol Number: |
B46 |
| Sponsors and Collaborators: |
NSABP (National Surgical Adjuvant Breast and Bowel Project) |
| Weblink: |
LINK TO THE WEB SITE |
| Title: |
A RANDOMIZED PHASE III TRIAL OF WEEKLY PACLITAXEL COMPARED TO WEEKLY NANOPARTICLE ALBUMIN BOUND NAB-PACLITAXEL OR IXABEPILONE COMBINED WITH BEVACIZUMABL AS FIRST LINE THERAPY FOR LOCALLY RECURRENT OR METASTATIC BREAST CANCER |
| Phase: |
III |
| Protocol Number: |
CALGB 40502 |
| Sponsors and Collaborators: |
Cancer Trials Support Unit |
| Weblink: |
LINK TO THE WEB SITE |
| Title: |
A PHASE II CLINICAL TRIAL OF FOUR CYCLES OF DOXORUBICIN AND CYCLOPHOSPHAMIDE FOLLOWED BY WEEKLY PACLITAXEL GIVEN CONCURRENTLY WITH PAZOPANIB AS NEOADJUVANT THERAPY FOLLOWED BY POSTOPERATIVE PAZOPANIB FOR WOMEN WITH LOCALLY ADVANCED BREAST CANCER |
| Phase: |
III |
| Protocol Number: |
110264 |
| Sponsors and Collaborators: |
GlaxoSmithKline |
| Weblink: |
LINK TO THE WEB SITE |
| Title: |
AN OPEN-LABEL, EXPANDED ACCESS PROTOCOL OF INIPARIB IN COMBINATION WITH GEMCITABINE/CARBOPLATIN IN PATIENTS WITH ER-, PR-, AND HER2-NEGATIVE METASTATIC BREAST CANCER |
| Phase: |
II |
| Protocol Number: |
2010EAP |
| Sponsors and Collaborators: |
BiPar Sciences |
| Weblink: |
LINK TO THE WEB SITE |
ONGOING STUDIES BUT CLOSED TO NEW PARTICIPANTS |
| Title: |
A RANDOMIZED PHASE III TRIAL OF NEOADJUVANT THERAPY IN PATIENTS WITH PALPABLE AND OPERABLE BREAST CANCER EVALUATING THE EFFECT ON PATHOLOGIC COMPLETE RESPONSE (PCR) OF ADDING CAPECITABINE OR GEMCITABINE TO DOCETAXEL WHEN ADMINISTERED BEFORE AC WITH OR WITHOUT BEVACIZUMAB AND CORRELATIVE SCIENCE STUDIES ATTEMPTING TO IDENTIFY PREDICTORS OF HIGH LIKELIHOOD FOR PCR WITH EACH OF THE REGIMENS |
| Phase: |
III |
| Protocol Number: |
B40 |
| Sponsors and Collaborators: |
NSABP (National Surgical Adjuvant Breast and Bowel Project ) |
| Weblink: |
LINK TO THE WEB SITE |
| Title: |
A MULTICENTER RANDOMIZED TRIAL OF ADJUVANT THERAPY FOR PATIENTS WITH HER2+ NODE+ OR HIGH RISK NODE NEGATIVE BREAST CANCER COMPARING CHEMOTHERAPY PLUS TRASTUZUMAB WITH CHEMOTHERAPY + TRASTUZUMAB PLUS BEVACIZUMAB |
| Phase: |
III |
| Modality: |
Chemotherapy |
| Sponsors and Collaborators: |
National Surgical Adjuvant Breast and Bowel Project (NSABP) |
| Protocol Number: |
B-44 |
| Weblink: |
LINK TO THE WEBSITE |
| Title: |
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PERTUZUMAB + TRASTUZUMAB + DOCETAXEL VS. PLACEBO + TRASTUZUMAB + DOCETAXEL IN PREVIOUSLY UNTREATED HER2-POSITIVE METASTATIC BREAST CANCER |
| Phase: |
III |
| Protocol Number: |
TOC4129g |
| Sponsors and Collaborators: |
Genentech |
| Weblink: |
LINK TO THE WEB SITE |
| Title: |
A PHASE 3, MULTI-CENTER STUDY OF GEMCITABINE/CARBOPLATIN, WITH OR WITHOUT BSI-201, IN PATIENTS WITH ER-, PR-, AND HER2-NEGATIVE METASTATIC BREAST CANCER |
| Phase: |
III |
| Protocol Number: |
BiPar |
| Sponsors and Collaborators: |
BiPar Sciences |
| Weblink: |
LINK TO THE WEB SITE |
